Drug Profile
INB 100
Alternative Names: DeltEx Allo - IN8bio; INB-100Latest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator IN8bio
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Leukaemia; Myelodysplastic syndromes
Most Recent Events
- 14 Mar 2024 Pharmacokinetics data from a phase I trial in Leukaemia and Myelodysplastic syndromes released by IN8bio
- 08 Jan 2024 IN8bio plans to submit an IND application for initiation of phase III trial of INB 100, in 2024
- 11 Dec 2023 Updated efficacy data from a phase I trial in Leukemia presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition